Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Exploring the Parkinson’s disease phenome in the UK Biobank population
Movement Disorders
P4 - Poster Session 4 (5:30 PM-6:30 PM)
3-003
To explore risk factors and comorbidities associated with a diagnosis of Parkinson’s disease (PD) in a broadly-phenotyped cohort.
PD is the second most common neurodegenerative disorder worldwide. Prevalence is expected to rise as the population ages. Nigral neuronal loss and Lewy body pathology are well established by the time a diagnosis is made, and there is a strong drive to identify people at the earliest possible stages to test neuroprotective/restorative therapies.
We extracted prevalent PD cases (n=1938) and unmatched controls (n=500595) from the UK Biobank cohort study. We carried out cross-sectional analysis of self-reported or hospital coded exposures in UK Biobank. Exposures of interest were identified from a previous systematic review of early features and risk factors for PD (Noyce 2012). We used logistic regression, adjusting for age and gender, to determine associations of these exposures with PD.
Mean age was 63(±5) and 57(±8) years in the PD and control group respectively. Factors associated with a diagnosis of PD were anxiety disorder (OR 5.07 95% CI 4.56-5.63), depression (OR 4.93 95% CI 4.52-5.36), excessive daytime sleepiness (OR 3.55 95% CI 3.03-4.17), family history of PD (OR 2.43 95% CI 2.21-2.68), pesticides exposure (OR 2.37 95% CI 1.78-3.17), diabetes (OR 1.44 95% CI 1.31-1.58) and being underweight (OR 1.75 95% CI 1.01-3.04). Factors associated with a lower risk of PD were current smoking (OR 0.63 95% CI 0.55-0.72), past history of smoking (OR 0.82 95% CI 0.77-0.88), and maternal smoking (OR 0.90 95% CI 0.83-0.97).
We confirm clear associations between odds of PD and the following traits: psychiatric comorbidity, diabetes, family history of PD, pesticide exposure and smoking status. Ultimately, greater value will be derived as incident cases of PD occur in the UK Biobank cohort. The current data support previous observational studies and highlight the robustness of self-reported phenotypes.
Authors/Disclosures
Daniel Belete, MBChB (Wolfson Institute of Preventive Medicine)
PRESENTER 		No disclosure on file
No disclosure on file
Anette E. Schrag, MD Dr. Schrag has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Otsuka. Dr. Schrag has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merz. Dr. Schrag has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boehringer ingelheim. Dr. Schrag has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bial. The institution of Dr. Schrag has received research support from NIHR, EU, Parkinson's UK, MDS.
Alastair J. Noyce, MBBS (Wolfson Institute of Preventive Medicine) Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for uMed. Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Noyce has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Charco NeuroTech. Dr. Noyce has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alchemab. Dr. Noyce has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MDS. Dr. Noyce has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BIAL. Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Oxford Pharmagenesis. Dr. Noyce has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for AstraZeneca. The institution of Dr. Noyce has received research support from Solvemed. The institution of Dr. Noyce has received research support from Alchemab.